Alumis (NASDAQ:ALMS) Azioni, Quote.MetaTitle.unusual-options

Alumis

Alumis Inc

Alto Neuroscience

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics

Arvinas

Canopy Growth Corporation - Common Shares

Canopy Growth

Cormedix

Cronos Group

Contineum Therapeutics, Inc. - Common stock

Contineum Therapeutics

Evolus

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics

Eton Pharmaceuticals, Inc. - Common Stock

Eton Pharmaceuticals

EyePoint Pharmaceuticals, Inc. - Common Stock

EyePoint Pharmaceuticals

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics

GH Research

LB Pharmaceuticals

LENZ Therapeutics

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Neumora Therapeutics, Inc. - Common Stock

Neumora Therapeutics

Omeros

Pacira BioSciences

Septerna

SIGA Technologies

SNDL

Theravance Biopharma, Inc. - Ordinary Shares

Theravance Biopharma

Ventyx Biosciences

Zevra Therapeutics

Alumis (ALMS) Previsione

Notizie

Utili

Quote.Nav.option-chain

Valutazioni degli analisti

Insider trading

Vendite allo scoperto

Rapporto azionario

Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.

Comments

Alumis Opzioni Inusuali

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO